Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers

References

• El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10.
   PubMedGoogle Scholar
• Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55–61.
   PubMedGoogle Scholar
• Braun J, Listing J, Sieper J. Reply. Arthritis Rheum. 2005;52(12):4049–4050.
   Google Scholar
• Jd T, Chhabra A, Ra C. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563–2574.
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Dougados M, et al. Axial spondyloarthritis. Nat Rev Primer. 2015;1(1):15013. .
   PubMed Web of Science ®Google Scholar
• Ermann J, Rao DA, Teslovich NC, et al. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat Rev Rheumatol. 2015;11(9):541–551. .
   PubMed Web of Science ®Google Scholar
• Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1009–1018.
   PubMed Web of Science ®Google Scholar
• Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234–240. .
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548. .
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681–1690. .
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNFα therapy ofrheumatoidarthritis: What have we learned? Annu Rev Immunol. 2001;19(1):163–196.
   PubMedGoogle Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–1405. .
   PubMed Web of Science ®Google Scholar
• Van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109(1):129–135. .
   PubMed Web of Science ®Google Scholar
• Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43(6):1346–1352. .
   PubMed Web of Science ®Google Scholar
• Menegatti S, Bianchi E, Rogge L. Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses. Front Immunol. 2019;10:382.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842–1847. .
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385–390. .
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521–1528.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43(1):38–47. .
   PubMed Web of Science ®Google Scholar
• Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41(7):1258–1265. .
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Wang XB, Ellis JJ, Pennisi DJ, et al. Transcriptome analysis of ankylosing spondylitis patients before and after TNF-alpha inhibitor therapy reveals the pathways affected. Genes Immun. 2017;18(3):184–190. .
   PubMed Web of Science ®Google Scholar
• Xu L, Sun Q, Jiang S, et al. Changes in gene expression profiles of the hip joint ligament of patients with ankylosing spondylitis revealed by DNA chip. Clin Rheumatol. 2012;31:1479–1491.
   PubMed Web of Science ®Google Scholar
• Goedecke V, Crane AM, Jaakkola E, et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun. 2003;4(1):74–76. .
   PubMed Web of Science ®Google Scholar
• Tsukazaki H, Kaito T. The role of the IL-23/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci. 2020;21(17):6401.
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Barnes MR, Blighe K, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;528(9):2455–2470. .
   Google Scholar
• Duffy D, Rouilly V, Libri V, et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity. 2014;40(3):436–450. .
   PubMed Web of Science ®Google Scholar
• Menegatti S, Guillemot V, Latis E, et al. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis. 2020; annrheumdis-2020-218304. 10.1136/annrheumdis-2020-218304.
   PubMed Web of Science ®Google Scholar
• Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14(1):177. .
   PubMedGoogle Scholar
• Yaari G, Bolen CR, Thakar J, et al. Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations. Nucleic Acids Res. 2013;41(18):e170.
   PubMed Web of Science ®Google Scholar
• Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(6):1548–1550.
   PubMed Web of Science ®Google Scholar
• Latis E, Michonneau D, Leloup C, et al. Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD. Blood Adv. 2020;4(16):3927–3942. .
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. .
   PubMed Web of Science ®Google Scholar
• Khanniche A, Zhou L, Jiang B, et al. Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment. Front Immunol. 2019;10:887.
   PubMed Web of Science ®Google Scholar
• Schett G, Neurath MF. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat Commun. 2018;9(1):3261.
   PubMedGoogle Scholar
• Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Aj S, Mj S, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285. .
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104. .
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884–1894. .
   PubMed Web of Science ®Google Scholar
• Marino S, Cilfone NA, Mattila JT, et al. Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection. Infect Immun. 2015;83(1):324–338. .
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–1057.
   PubMed Web of Science ®Google Scholar
• Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731–741.
   PubMed Web of Science ®Google Scholar
• Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med. 2009;206(3):535–548. .
   PubMed Web of Science ®Google Scholar
• Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: hype or Reality in 2020? Can we predict response to anti-TNF? Front Med Lausanne. 2020;7:517.
   PubMed Web of Science ®Google Scholar
• Sutcliffe M, Radley G, Barton A. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors? Expert Rev Clin Immunol. 2020;16(4):389–396.
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53. .
   PubMed Web of Science ®Google Scholar
• Machado P, Navarro-Compan V, Landewe R, et al. Calculating the ankylosing spondylitis disease activity score if the conventional C-reactive protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol. 2015;67(2):408–413. .
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489.
   PubMed Web of Science ®Google Scholar
• Bank S, Julsgaard M, Abed OK, et al. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):890–903.
   PubMed Web of Science ®Google Scholar
• Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14(6):526–534.
   PubMed Web of Science ®Google Scholar
• Dahlén R, Magnusson MK, Bajor A, et al. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy. Scand J Gastroenterol. 2015;50(9):1118–1126.
   PubMed Web of Science ®Google Scholar
• Rismo R, Olsen T, Cui G, et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47(5):538–547. .
   PubMed Web of Science ®Google Scholar
• Belarif L, Danger R, Kermarrec L, et al., IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest. 129(5): 1910–1925. 2019. .
   PubMed Web of Science ®Google Scholar
• D’Haens G, Kelly O, Battat R, et al. Development and validation of a test to monitor endoscopic activity in patients with crohn’s disease based on serum levels of proteins. Gastroenterology. 2020;10(3):515–526.
   Google Scholar
• Xie X, Li F, Li S, et al. Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis. Clin Rheumatol. 2018;37(1):13–23. .
   PubMed Web of Science ®Google Scholar
• Aterido A, Cañete JD, Tornero J, et al. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-tnf therapy in rheumatoid arthritis. Front Immunol. 2019;10:1459.
   PubMed Web of Science ®Google Scholar
• Barberà-Cremades M, Baroja-Mazo A, Pelegrín P. Purinergic signaling during macrophage differentiation results in M2 alternative activated macrophages. J Leukoc Biol. 2016;99(2):289–299.
   PubMed Web of Science ®Google Scholar
• Bours MJL, Swennen ELR, Di Virgilio F, et al. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112:358–404.
   PubMed Web of Science ®Google Scholar
• Barton A, Pitzalis C. Stratified medicine in rheumatoid arthritis-the MATURA programme. Rheumatol Oxf Engl. 2017;56(8):1247–1250.
   PubMed Web of Science ®Google Scholar
• Cherlin S, Lewis MJ, Plant D, et al. Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response. Ann Rheum Dis. 2020;79(11):1446–1452.
   PubMed Web of Science ®Google Scholar
• Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2011;31(10):745–751.
   PubMed Web of Science ®Google Scholar
• Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn’s disease. Inflamm Bowel Dis. 2010;16(12):2090–2098. .
   PubMed Web of Science ®Google Scholar
• Medrano LM, Taxonera C, González-Artacho C, et al. Response to Infliximab in Crohn’s disease: Genetic analysis supporting expression profile. Mediators Inflamm. 2015;2015:318207.
   PubMed Web of Science ®Google Scholar
• Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58(12):1612–1619. .
   PubMed Web of Science ®Google Scholar
• Brown MA, Li Z, Cao K-AL. Biomarker development for axial spondyloarthritis. Nat Rev Rheumatol. 2020;16:448–463.
   PubMed Web of Science ®Google Scholar
• Gibson G. On the utilization of polygenic risk scores for therapeutic targeting. Barsh GS, editor. PLOS Genet. 2019;15(4):e1008060.
   PubMed Web of Science ®Google Scholar
• Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev. 2019;73:20–30.
   PubMed Web of Science ®Google Scholar
• Jurgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: Molecular markers and clinical trial designs. Clin Cancer Res. 2014;20(17):4425–4435.
   PubMed Web of Science ®Google Scholar
• Wray NR, Yang J, Hayes BJ, et al. Pitfalls of predicting complex traits from SNPs. Nat Rev Genet. 2013;14(7):507–515. .
   PubMed Web of Science ®Google Scholar
• Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation and its contribution to complex traits. Nat Rev Genet. 2009;10(4):241–251.
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmuller U, Moller B, et al. The −308 tumour necrosis factor-gene polymorphism predicts therapeutic response to TNF-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology. 2007;46(1):93–96.
   PubMed Web of Science ®Google Scholar
• Liu J, Dong Z, Zhu Q, et al. TNF-α promoter polymorphisms predict the response to etanercept more powerfully than that to infliximab/adalimumab in spondyloarthritis. Sci Rep. 2016;6(1):32202. .
   PubMedGoogle Scholar
• Fabris M, Quartuccio L, Fabro C, et al. The −308 TNFα and the −174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. Pharmacogenomics J. 2016;16(3):238–242. .
   PubMed Web of Science ®Google Scholar
• Aita A, Basso D, Ramonda R, et al. Genetics in TNF-TNFR pathway: a complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy. Chang Y-J, editor. PLoS One. 2018;13(3):e0194693. .
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-tnf-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhu Q, Han J, et al. IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis. Mol Med. 2019;25(1). DOI:10.1186/s10020-019-0093-2.
   Google Scholar
• Jp Y L B, Campos J, Sanz J, et al. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis. Int J Rheum Dis. 2019;22(8):1529–1537.
   PubMed Web of Science ®Google Scholar
• Ovejero‐Benito MC, Reolid A, Sánchez‐Jiménez P, et al. Histone modifications associated with biological drug response in moderate‐to‐severe psoriasis. Exp Dermatol. 2018;27(12):1361–1371. .
   PubMed Web of Science ®Google Scholar
• Ciechomska M, Bonek K, Merdas M, et al. Changes in MiRNA-5196 expression as a potential biomarker of anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis patients. Arch Immunol Ther Exp (Warsz). 2018;66(5):389–397. .
   PubMed Web of Science ®Google Scholar
• Arends S, Van Der Veer E, Groen H, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol. 2011;38(8):1644–1650. .
   PubMed Web of Science ®Google Scholar
• Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis. 2012;71(5):674–680. .
   PubMed Web of Science ®Google Scholar
• Ademowo OS, Hernandez B, Collins E, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2016;75(1):234–241. .
   PubMed Web of Science ®Google Scholar
• Turina MC, Yeremenko N, Paramarta JE, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16(4). 10.1186/s13075-014-0413-4.
   PubMed Web of Science ®Google Scholar
• Østgård R, Deleuran B, Dam M, et al. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol. 2018;47(1):48–55.
   PubMed Web of Science ®Google Scholar
• Hu H, Du F, Zhang S, et al. Serum calprotectin correlates with risk and disease severity of ankylosing spondylitis and its change during first month might predict favorable response to treatment. Mod Rheumatol. 2019;29(5):836–842.
   PubMed Web of Science ®Google Scholar
• Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 10522 (2020)
   Google Scholar
• Baraliakos X, Szumski A, Koenig AS, et al. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2019;48(6):997–1004.
   PubMed Web of Science ®Google Scholar
• Hokstad I, Deyab G, Wang Fagerland M, et al. Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: an observational study. Miyabe Y, editor. Plos One. 2019;14(7):e0220079. .
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Perricone C, Graceffa D, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30(1):23–30.
   PubMed Web of Science ®Google Scholar
• Dolcino M, Tinazzi E, Pelosi A, et al. Gene expression analysis before and after treatment with adalimumab in patients with ankylosing spondylitis identifies molecular pathways associated with response to therapy. Genes (Basel). 2017;8(4):127. .
   PubMed Web of Science ®Google Scholar
• Enginar AU, Kacar C. Neutrophil-lymphocyte and platelet-lymphocyte rate and their seasonal differences in ankylosing spondylitis and rheumatoid arthritis patients using anti-TNF medication. Bratisl Med J. 2019;120(8):586–592.
   Google Scholar
• Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology. 2019;58(2):336–344.
   PubMed Web of Science ®Google Scholar
• Schulte-Wrede U, Sörensen T, Grün JR, et al. An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. Arthritis Res Ther. 2018;20(1). 10.1186/s13075-018-1692-y.
   PubMedGoogle Scholar
• Dulic S, Vasarhelyi Z, Bajnok A, et al. The impact of anti-TNF Therapy on CD4+ and CD8+ cell subsets in ankylosing spondylitis. Pathobiology. 2018;85(3):201–210. .
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, et al. Levels of CIrculating Th17 Cells and Regulatory T cells in ankylosing spondylitis patients with an inadequate response to Anti−TNF-α Therapy. J Clin Immunol. 2013;33(1):151–161.
   PubMed Web of Science ®Google Scholar
• Andersen T, Østgård RD, Aspari MP, et al. Anti-tumor necrosis factor treatment increases both the Th17 and Th22 T helper subsets in spondyloarthritis. APMIS. 2019;127(12):789–796. .
   PubMed Web of Science ®Google Scholar
• Yang M, Lv Q, Wei Q, et al. TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis. Arthritis Res Ther. 2020;22(1):149. .
   PubMed Web of Science ®Google Scholar
• Pavy S, Toonen EJM, Miceli-Richard C, et al. Tumour necrosis factor alpha −308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2010;69(6):1022–1028.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Duan Z, Zhang T, et al. Association between tumor necrosis factor-α (TNF-α) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2013;23(3):489–495. .
   PubMed Web of Science ®Google Scholar
• Cui J, Stahl EA, Saevarsdottir S, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9(3):e1003394. .
   PubMed Web of Science ®Google Scholar
• Swierkot J, Bogunia-Kubik K, Nowak B, et al. Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(2):94–99. .
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias A, Montes A, Perez-Pampin E, et al. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J. 2016;16(2):137–140.
   PubMed Web of Science ®Google Scholar
• Honne K, Hallgrímsdóttir I, Wu C, et al. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):12. .
   PubMedGoogle Scholar
• Julià A, Fernandez-Nebro A, Blanco F, et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 2016;16(2):147–150.
   PubMed Web of Science ®Google Scholar
• Cui J, Diogo D, Stahl EA, et al. Brief report: The role of rare protein-coding variants in anti-tumor necrosis factor treatment response in rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ. 2017;69(4):735–741.
   PubMed Web of Science ®Google Scholar
• Marwa OS, Kalthoum T, Wajih K, et al. Association of IL17A and IL17F genes with rheumatoid arthritis disease and the impact of genetic polymorphisms on response to treatment. Immunol Lett. 2017;183:24–36.
   PubMed Web of Science ®Google Scholar
• Sieberts SK, Zhu F, García-García J, et al., Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 7(1): 12460. 2016. .
   PubMedGoogle Scholar
• Cherlin S, Plant D, Taylor JC, et al. Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. Genet Epidemiol. 2018;42(8):754–771.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang H, Quang D, et al. machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers. Arthritis Rheumatol Hoboken NJ. 2019;71(12):1987–1996.
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias A, Montes A, Perez-Pampin E, et al. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. PloS One. 2019;14(2):e0213073. .
   PubMed Web of Science ®Google Scholar
• Bai M, He X, He Y, et al. IL-7R gene polymorphisms among patients with rheumatoid arthritis: a case-control study. Mol Genet Genomic Med. 2019;7(7):e00738.
   PubMed Web of Science ®Google Scholar
• Castro-Villegas C, Pérez-Sánchez C, Escudero A, et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015;17(1):49.
   PubMedGoogle Scholar
• Krintel SB, Dehlendorff C, Hetland ML, et al. Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis. Pharmacogenomics J. 2016;16(2):141–146.
   PubMed Web of Science ®Google Scholar
• Oswald M, Curran ME, Lamberth SL, et al. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol Hoboken NJ. 2015;67(2):344–351. .
   PubMed Web of Science ®Google Scholar
• Huang Q-L, Zhou F-J, Wu C-B, et al. Circulating biomarkers for predicting infliximab response in rheumatoid arthritis: a systematic bioinformatics analysis. Med Sci Monit Int Med J Exp Clin Res. 2017;23:1849–1855.
   Google Scholar
• Byng-Maddick R, Turner CT, Pollara G, et al. tumor necrosis factor (TNF) bioactivity at the site of an acute cell-mediated immune response is preserved in rheumatoid arthritis patients responding to anti-TNF therapy. Front Immunol. 2017;8:932.
   PubMed Web of Science ®Google Scholar
• Shi R, Chen M, Litifu B. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis. Mod Rheumatol. 2018;28(1):126–132.
   PubMed Web of Science ®Google Scholar
• Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study. Arthritis Res Ther. 2016;18:93.
   PubMed Web of Science ®Google Scholar
• Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45–51. .
   PubMed Web of Science ®Google Scholar
• Curtis JR, Van Der Helm-van Mil AH, Knevel R, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res. 2012;64(12):1794–1803. .
   PubMed Web of Science ®Google Scholar
• Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PloS One. 2013;8(4):e60635.
   PubMed Web of Science ®Google Scholar
• Hirata S, Li W, Defranoux N, et al. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study. Mod Rheumatol. 2015;25(3):344–349.
   PubMed Web of Science ®Google Scholar
• Hirata S, Li W, Kubo S, et al. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Mod Rheumatol. 2016;26(6):850–856.
   PubMed Web of Science ®Google Scholar
• Li W, Sasso EH, Van Der Helm-van Mil AHM, et al. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatol Oxf Engl. 2016;55(2):357–366. .
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Connolly SE, Maldonado MA, et al. Brief report: Estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab. Arthritis Rheumatol Hoboken NJ. 2016;68(9):2083–2089.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Bolce RJ, Saevarsdottir S, et al. Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2016;2(1):e000197. .
   PubMed Web of Science ®Google Scholar
• Rech J, Hueber AJ, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75(9):1637–1644. .
   PubMed Web of Science ®Google Scholar
• Hambardzumyan K, Saevarsdottir S, Forslind K, et al. A multi-biomarker disease activity score and the choice of second-line therapy in early rheumatoid arthritis after methotrexate failure. Arthritis Rheumatol Hoboken NJ. 2017;69(5):953–963. .
   PubMed Web of Science ®Google Scholar
• Krabbe S, Bolce R, Brahe CH, et al. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. Scand J Rheumatol. 2017;46(5):353–358. .
   PubMed Web of Science ®Google Scholar
• Bouman CAM, Van Der Maas A, Van Herwaarden N, et al. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. Rheumatol Oxf Engl. 2017;56(6):973–980.
   PubMed Web of Science ®Google Scholar
• Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PloS One. 2018;13(5):e0192425. .
   PubMed Web of Science ®Google Scholar
• Bechman K, Tweehuysen L, Garrood T, et al. Flares in rheumatoid arthritis patients with low disease activity: predictability and association with worse clinical outcomes. J Rheumatol. 2018;45(11):1515–1521.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Brahe CH, Østergaard M, et al. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. Curr Med Res Opin. 2019;35(9):1483–1493.
   PubMed Web of Science ®Google Scholar
• Cuppen B, Fritsch-Stork R, Eekhout I, et al. Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score. Scand J Rheumatol. 2018;47(1):12–21.
   PubMed Web of Science ®Google Scholar
• Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505. .
   PubMed Web of Science ®Google Scholar
• Nair SC, Welsing PMJ, Choi IYK, et al. A personalized approach to biological therapy using prediction of clinical response based on mrp8/14 serum complex levels in rheumatoid arthritis patients. PloS One. 2016;11(3):e0152362.
   PubMed Web of Science ®Google Scholar
• Nordal HH, Brun JG, Hordvik M, et al. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab. Scand J Rheumatol. 2016;45(4):274–281. .
   PubMed Web of Science ®Google Scholar
• Smith SL, Plant D, Eyre S, et al. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatol Oxf Engl. 2017;56:1019–1024.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, Den Broeder N, Van Herwaarden N, et al. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654.
   PubMed Web of Science ®Google Scholar
• Yunchun L, Yue W, Jun FZ, et al. Clinical significance of myeloid-related protein 8/14 as a predictor for biological treatment and disease activity in rheumatoid arthritis. Ann Clin Lab Sci. 2018;48(1):63–68.
   PubMed Web of Science ®Google Scholar
• De Moel EC, Rech J, Mahler M, et al. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs. Arthritis Res Ther. 2019;21(1):268. .
   PubMed Web of Science ®Google Scholar
• Daien CI, Gailhac S, Mura T, et al. High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthritis Res Ther. 2014;16(2):R95.
   PubMed Web of Science ®Google Scholar
• Citro A, Scrivo R, Martini H, et al. CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis. PloS One. 2015;10(6):e0128607.
   PubMed Web of Science ®Google Scholar
• Hull DN, Cooksley H, Chokshi S, et al. Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):303.
   PubMedGoogle Scholar
• Salomon S, Guignant C, Morel P, et al. Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):33. .
   PubMedGoogle Scholar
• Lee H-N, Kim Y-K, Kim G-T, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis. Rheumatol Int. 2019;39:859–868.
   PubMed Web of Science ®Google Scholar
• Cianciotti BC, Ruggiero E, Campochiaro C, et al. CD4+ memory stem T cells recognizing citrullinated epitopes are expanded in patients with rheumatoid arthritis and sensitive to tumor necrosis factor blockade. Arthritis Rheumatol Hoboken NJ. 2020;72(4):565–575.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Martín E, Nieto-Gañán I, Hernández-Breijo B, et al. Blood lymphocyte subsets for early identification of non-remission to TNF inhibitors in rheumatoid arthritis. Front Immunol. 2020;11:1913.
   PubMed Web of Science ®Google Scholar
• Bystrom J, Clanchy FI, Taher TE, et al. Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T Lymphocytes. Clin Rev Allergy Immunol. 2017;53(2):265–276. .
   PubMed Web of Science ®Google Scholar
• Lliso-Ribera G, Humby F, Lewis M, et al. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann Rheum Dis. 2019;78(12):1642–1652. .
   PubMed Web of Science ®Google Scholar
• Massey J, Plant D, Hyrich K, et al. Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics J. 2018;18(5):657–664. .
   PubMed Web of Science ®Google Scholar
• Farutin V, Prod’homme T, McConnell K, et al., Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor. Arthritis Res Ther. 21(1): 216. 2019. .
   PubMed Web of Science ®Google Scholar
• Tao W, Concepcion AN, Vianen M, et al. Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ. 2020.
   PubMed Web of Science ®Google Scholar
• Spiliopoulou A, Colombo M, Plant D, et al., Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD4 and CD39. Ann Rheum Dis. 78(8): 1055–1061. 2019. .
   PubMed Web of Science ®Google Scholar
• Folkersen L, Brynedal B, Diaz-Gallo LM, et al. Integration of known DNA, RNA and protein biomarkers provides prediction of anti-TNF response in rheumatoid arthritis: results from the COMBINE study. Mol Med. 2016;22:322–328.
   PubMed Web of Science ®Google Scholar
• Tasaki S, Suzuki K, Kassai Y, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun. 2018;9(1):2755. .
   PubMedGoogle Scholar
• Wang M-H, Friton JJ, Raffals LE, et al. Novel genetic risk variants can predict anti-tnf agent response in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13(8):1036–1043. .
   PubMed Web of Science ®Google Scholar
• Gomez A, Ingelman‐Sundberg M. Pharmacoepigenetics: Its role in interindividual differences in drug response. Clin Pharmacol Ther. 2009;85(4):426–430.
   PubMed Web of Science ®Google Scholar
• Cherqaoui B, Crémazy F, Hue C, et al. Epigenetics of spondyloarthritis. Joint Bone Spine. 2020;87(6):565–571.
   PubMed Web of Science ®Google Scholar
• Aslani S, Mahmoudi M, Karami J, et al. Epigenetic alterations underlying autoimmune diseases. Autoimmunity. 2016;49(2):69–83. .
   PubMed Web of Science ®Google Scholar
• Toonen EJM, Gilissen C, Franke B, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One. 2012;7(3):e33199.
   PubMed Web of Science ®Google Scholar
• Reinhardt A, Prinz I. Whodunit? The contribution of interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and innate lymphoid cells to the pathogenesis of spondyloarthritis. Front Immunol. 2018;9:885.
   PubMed Web of Science ®Google Scholar
• Huang Y, Deng W, Zheng S, et al. Relationship between monocytes to lymphocytes ratio and axial spondyloarthritis. Int Immunopharmacol. 2018;57:43–46.
   PubMed Web of Science ®Google Scholar
• Uslu AU, Küçük A, Şahin A, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis. 2015;18(7):731–735. .
   PubMed Web of Science ®Google Scholar
• Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016;30(5):597–601. .
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hosomi S, Yamagami H, et al. Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitisone. PLOS. 2017;12(1):e0169845.
   Google Scholar
• Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell. 2019;e20(178):1493–1508.
   Google Scholar
• Lorenzin M, Ometto F, Ortolan A, et al. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis. 2020;12:1759720X2093427.
   Web of Science ®Google Scholar
• Bal A, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26(2):211–215.
   PubMed Web of Science ®Google Scholar
• Arends S, Van Der Veer E, Kallenberg CGM, et al. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol. 2012;24(3):290–298.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol. 2019;10. 10.3389/fimmu.2019.00305
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Value of the multibiomarker disease activity score to predict remission in RA: What does the evidence show? J Rheumatol. 2019;46(5):443–446.
   PubMed Web of Science ®Google Scholar
• Calabrese LH. MBDA: A valuable tool for medical decision making. J Rheumatol. 2019;46(12):1642.
   PubMed Web of Science ®Google Scholar
• Masi AT. What further data are needed to value the multi-biomarker disease activity score for measuring rheumatoid arthritis disease activity: comment on the article by Johnson et al. Arthritis Care Res. 2020;72(9):1339–1340.
   Web of Science ®Google Scholar
• Van Der Helm-van Mil AHM, Knevel R, Cavet G, et al. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatol Oxf Engl. 2013;52(5):839–846.
   PubMed Web of Science ®Google Scholar
• Romand X, Bernardy C, Nguyen MVC, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine. 2019;86(6):691–698.
   PubMed Web of Science ®Google Scholar
• Austermann J, Spiekermann C, Roth J. S100 proteins in rheumatic diseases. Nat Rev Rheumatol. 2018;14(9):528–541.
   PubMed Web of Science ®Google Scholar
• Sun S, Bay-Jensen A-C, Karsdal MA, et al. The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord. 2014;15(1):93.
   PubMedGoogle Scholar
• Gao JW, Zhang KF, Lu JS, et al. Serum matrix metalloproteinases-3 levels in patients with ankylosing spondylitis. Genet Mol Res GMR. 2015;14(4):17068–17078.
   PubMed Web of Science ®Google Scholar
• Mou Y-K, Zhang -P-P, Li Q-X, et al. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes. Clin Rheumatol. 2015;34(6):1085–1089.
   PubMed Web of Science ®Google Scholar
• Jadon DR, Sengupta R, Nightingale A, et al. Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Res Ther. 2017;19(1):210. .
   PubMedGoogle Scholar
• Moz S, Aita A, Basso D, et al. Spondyloarthritis: matrix metalloproteinases as biomarkers of pathogenesis and response to tumor necrosis factor (TNF) Inhibitors. Int J Mol Sci. 2017;18(4):830.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29(11):1301–1309. .
   PubMed Web of Science ®Google Scholar
• Chandran V, Shen H, Pollock RA, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40(6):866–871.
   PubMed Web of Science ®Google Scholar
• Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–291.
   PubMed Web of Science ®Google Scholar
• Minar P, Lehn C, Tsai Y-T, et al. Elevated pretreatment plasma oncostatin m is associated with poor biochemical response to infliximab. Crohns Colitis. 2019;1:otzO26.
   Google Scholar
• West NR, Hegazy AN, Owens BMJ, et al., Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 23(5): 579–589. 2017.
   PubMed Web of Science ®Google Scholar
• West NR. Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front Immunol. 2019;10. 10.3389/fimmu.2019.01093
   Web of Science ®Google Scholar